Home Dashboard References

References

References

Abdou NI, et al. Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults. Int Arch Allergy Immunol. 2009;149(3):267-274.

Amgen Assist. Reimbursement for physician-purchased and physician-administered drugs: Understanding the buy and bill process. Publication no 60889-R5-V1.

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.

Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355-366.

Haas DA, Krosner YC, Mukerji N, Kaplan RS. Delivering higher value care means spending more time with patients. Harvard Business Review. December 26, 2014. Available at

James J, Hibbard J, Agres T, Lott R, Dentzer S. Patient engagement. Health Policy Briefs. February 14, 2013. Available at

Managing an in-office infusion practice. The Rheumatologist. August 8, 2012. Accessed May 17, 2017.

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitGerald JM, Chetta A, Humbert M, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. Lancet Respir Med. 2015;3(5):355-366.

The Joint Commission. Ambulatory care accreditation overview. 2017. Available at

Versel N. Build your own infusion clinic. Biotechnol Healtc. 2005; 2(1):35-36, 39-40. Available at

Links Provided in This Toolkit

CE Programs

  • Accreditation Association for Ambulatory Health Care, Inc.:
  • CE for infusion nurses:
  • Recertification for infusion nurses:
  • Standards of Practice for Infusion Nurses (eBook for purchase):
  • CE for billing and coding staff:

Guidance for Prior Authorization

Medication Guides
(list not all-inclusive; representative sampling only)

  • Omalizumab (Xolair):
  • Mepolizumab (Nucala):
  • Reslizumab (Cinqair):
  • Gammagard (IVIG or SCIG) FAQs:
  • Gamunex-C (IVIG or SCIG): Prescribing Information and Medication Guide:
  • Privigen (IVIG):
    • Practitioner/Clinician Infusion Guide:
    • Patient Support Services (a top-line guide):

Marketing Resources

  • PracticeDock. How to create an amazingly successful physician marketing plan & budget.
  • Gelb. Physician marketing & outreach.

National Infusion Center Association

Patient Assistance Programs

(list not all-inclusive; representative sampling only)

  • Omalizumab (Xolair):
  • Mepolizumab (Nucala):
  • Reslizumab (Cinqair):
  • Gammagard (IVIG or SCIG)FAQs: or
  • Gamunex-C (IVIG or SCIG):
  • Privigen (IVIG):

Payment Allowances for Medicare Part B Drugs